Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes

被引：59
作者：
Voso, M. T. [1 ]
Fabiani, E. [1 ]
D'Alo, F. [1 ]
Guidi, F. [1 ]
Di Ruscio, A. [1 ]
Sica, S. [1 ]
Pagano, L. [1 ]
Greco, M. [1 ]
Hohaus, S. [1 ]
Leone, G. [1 ]
机构：
[1] Univ Cattolica Sacro Cuore, Ist Ematol, I-00168 Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷 / 09期
关键词：
acute myeloid leukaemia; detoxification; DNA-repair; polymorphisms;
D O I：
10.1093/annonc/mdm191
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Polymorphisms in genes involved in detoxification and DNA-repair pathways may modify the individual's risk for genomic damage, and, as a consequence, the risk of developing malignant diseases. Patients and methods: We performed a case-control study including 160 cases of acute myeloid leukaemia (AML) and 162 matched controls to test the impact of six genomic polymorphisms on the risk to develop AML and/or therapy-related AML. Results: We found a significantly higher prevalence of the polymorphic variants RAD51-G135C and CYP3A4-A-290G genes in AML cases, when compared with controls (P = 0.02 and P = 0.04), increasing the risk of AML 2.1-folds (95% CI: 1.1-4.0) and 3.2-fold (95% CI: 1.1-11.5), respectively. Carriers of both the RAD51-G135C and CYP3A4-A290G variants were at highest AML risk (P = 0.003; OR: 13,6; 95% CI: 2.0-585.5), suggesting a synergistic effect between these polymorphisms. Conclusions: These results suggest that polymorphic variants in DNA-repair and detoxification enzymes may co-operate in modulating the individual's risk of AML.
引用
收藏
页码：1523 / 1528
页数：6
相关论文
共 31 条
[1]  
AliOsman F, 1997, J BIOL CHEM, V272, P10004
[2]   Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia [J].
Allan, JM ;
Wild, CP ;
Rollinson, S ;
Willett, EV ;
Moorman, AV ;
Dovey, GJ ;
Roddam, PL ;
Roman, E ;
Cartwright, RA ;
Morgan, GJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (20) :11592-11597
[3]   Increased transcriptional activity of the CYP3A4* 1B promoter variant [J].
Amirimani, B ;
Ning, B ;
Deitz, AC ;
Weber, BL ;
Kadlubar, FF ;
Rebbeck, TR .
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2003, 42 (04) :299-305
[4]   Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression [J].
Coles, BF ;
Morel, F ;
Rauch, C ;
Huber, WW ;
Yang, M ;
Teitel, CH ;
Green, B ;
Lang, NP ;
Kadlubar, FF .
PHARMACOGENETICS, 2001, 11 (08) :663-669
[5]  
D'Alo F, 2004, HAEMATOLOGICA, V89, P664
[6]   Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard group and the role of glutathione S-transferases [J].
Dirven, HAAM ;
vanOmmen, B ;
vanBladeren, PJ .
CHEMICAL RESEARCH IN TOXICOLOGY, 1996, 9 (02) :351-360
[7]   Association of CYP3A4 genotype with treatment-related leukemia [J].
Felix, CA ;
Walker, AH ;
Lange, BJ ;
Williams, TM ;
Winick, NJ ;
Cheung, NKV ;
Lovett, BD ;
Nowell, PC ;
Blair, IA ;
Rebbeck, TR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (22) :13176-13181
[8]   Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS [J].
Fern, L ;
Pallis, M ;
Carter, GI ;
Seedhouse, C ;
Russell, N ;
Byrne, J .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 126 (01) :63-71
[9]   The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997 [J].
Harris, NL ;
Jaffe, ES ;
Diebold, J ;
Flandrin, G ;
Muller-Hermelink, HK ;
Vardiman, J ;
Lister, TA ;
Bloomfield, CD .
MODERN PATHOLOGY, 2000, 13 (02) :193-207
[10]   Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma [J].
Hohaus, S ;
Di Ruscio, A ;
Di Febo, A ;
Massini, G ;
D'Alo, F ;
Guidi, F ;
Mansueto, G ;
Voso, MT ;
Leone, G .
CLINICAL CANCER RESEARCH, 2005, 11 (06) :2175-2179
1234